Evidence map›Paper›PMID 32407399›Full record

ArticlePloS one2020

Cuminaldehyde potentiates the antimicrobial actions of ciprofloxacin against Staphylococcus aureus and Escherichia coli.

Valério Monteiro-Neto, Cláudio D de Souza, Laoane F Gonzaga, Bruna C da Silveira, Nágila C F Sousa, Jaqueline P Pontes, Deivid M Santos, Wanessa C Martins, Jorge F V Pessoa, Alexsander R Carvalho Júnior and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Management of Enterococcus faecalis biofilms: a combinatorial approach with phytochemical.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. In Silico and In Vitro Analysis of Sulforaphane Anti-Antibiotics (Basel, Switzerland) · 2022
    Article
  19. Aqueous Extract fromFoods (Basel, Switzerland) · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Valério Monteiro-NetoPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.ORCID 0000-0003-2868-1314
Cláudio D de SouzaPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Laoane F GonzagaPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Bruna C da SilveiraInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Nágila C F SousaPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Jaqueline P PontesPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Deivid M SantosPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Wanessa C MartinsPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Jorge F V PessoaPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Alexsander R Carvalho JúniorDepartment of Parasitology, Universidade de São Paulo, São Paulo, SP, Brazil.
Viviane S S AlmeidaUniversidade Federal do Maranhão, São Luís, MA, Brazil.
Natália M T de OliveiraInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Thayla S de AraújoPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Daniele Maria-FerreiraInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Saulo J F MendesPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.ORCID 0000-0003-1628-3554
Thiago A F FerroPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.
Elizabeth S FernandesPrograma de Pós-graduação, Universidade Ceuma, São Luís, MA, Brazil.ORCID 0000-0002-0567-2514
Universidade Ceuma · BRUniversidade de São Paulo · BRUniversidade Federal do Maranhão · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Escherichia coli and Staphylococcus aureus are important agents of urinary tract infections that can often evolve to severe infections. The rise of antibiotic-resistant strains has driven the search for novel therapies to replace the use or act as adjuvants of antibiotics. In this context, plant-derived compounds have been widely investigated. Cuminaldehyde is suggested as the major antimicrobial compound of the cumin seed essential oil. However, this effect is not fully understood. Herein, we investigated the in silico and in vitro activities of cuminaldehyde, as well as its ability to potentiate ciprofloxacin effects against S. aureus and E. coli. In silico analyses were performed by using different computational tools. The PASS online and SwissADME programmes were used for the prediction of biological activities and oral bioavailability of cuminaldehyde. For analysis of the possible toxic effects and the theoretical pharmacokinetic parameters of the compound, the Osiris, SwissADME and PROTOX programmes were used. Estimations of cuminaldehyde gastrointestinal absorption, blood brain barrier permeability and skin permeation by using SwissADME; and drug likeness and score by using Osiris, were also evaluated The in vitro antimicrobial effects of cuminaldehyde were determined by using microdilution, biofilm formation and time-kill assays. In silico analysis indicated that cuminaldehyde may act as an antimicrobial and as a membrane permeability enhancer. It was suggested to be highly absorbable by the gastrointestinal tract and likely to cross the blood brain barrier. Also, irritative and harmful effects were predicted for cuminaldehyde if swallowed at its LD50. Good oral bioavailability and drug score were also found for this compound. Cuminaldehyde presented antimicrobial and anti-biofilm effects against S. aureus and E. coli.. When co-incubated with ciprofloxacin, it enhanced the antibiotic antimicrobial and anti-biofilm actions. We suggest that cuminaldehyde may be useful as an adjuvant therapy to ciprofloxacin in S. aureus and E. coli-induced infections.

Indexed as

Adjuvants, PharmaceuticAdministration, OralAnti-Bacterial AgentsBenzaldehydesBiofilmsBiological AvailabilityCiprofloxacinComputer SimulationCymenesDrug SynergismEscherichia coliEscherichia coli InfectionsHumansIn Vitro TechniquesMicrobial Sensitivity TestsStaphylococcal InfectionsAdjuvants, PharmaceuticAnti-Bacterial AgentsBenzaldehydesCiprofloxacincuminaldehydeCymenes

Identifiers

PMID32407399
PMCPMC7224478
OpenAlexW3025502539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.